Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
The buyout, announced last summer, drew the attention of federal regulators at the Federal Trade Commission, concerned that competition for ambulatory surgery services would be stifled by the merger. To appease the agency, Ascension has agreed to divest from some centers previously owned by Amsurg.
When Mayo Clinic and Microsoft announced last week that they’re partnering to develop a frontier AI model for healthcare, observers could see where Mayo’s expertise in advanced digital medicine would interest Microsoft. The Big Tech behemoth has not been coy about its healthcare ambitions.
If healthcare AI is to flourish outside of academic research settings and industry R&D departments, it will need to win over its most difficult-to-impress audience: healthcare workers in hospitals.
It stands to reason that the branch of healthcare most reliant on the use of language in clinical practice would embrace large language AI. But is U.S. mental healthcare on board with the notion?
Malissa Wood, MD, associate chief of cardiology for diversity and equity at Massachusetts General Hospital, explains the role of health equity in cardiovascular care and what her health system is doing to address it.
A new analysis reveals that insurers could put between $228 million and $2.15 billion back in taxpayers’ pockets by purchasing a series of generic oncology medications at the same prices obtained by the Mark Cuban Cost Plus Drug Company.